|
Erstellt von Léo Ponsard
vor etwa 7 Jahre
|
|
rituximab
obinutuzumab
catumaxomab
palivizumab
abciximab
alemtuzumab
adalimumab
infliximab
golimumab
certolizumab
basiliximab
daclizumab
trastuzumab
pertuzumab
cetuximab
panitumumab
natalizumab
vedolizumab
efalizumab
tocilizumab
ipilimumab
bevacizumab
ranibizumab
omalizumab
eculizumab
ustekinumab
siltuximab
sécukinumab
dénosumab
canakinumab
belimuman
Iode 131-tositumomab
ibritumomab tiuxetan
gemtuzumab ozogamycine
brentuximab vedotin
trastuzumab emtansine
EMD-273066
moxetumomab
stratégie ADEPT
abatacept